Labiotech.eu

thrombosis bayer healthcare isis pharmaceuticals

News and Trends 5 May 2015

Isis Pharmaceuticals and Bayer HealthCare team up to prevent thrombosis

Isis Pharmaceuticals and Bayer HealthCare will develop and commercialize ISIS-FXIRx for the prevention of thrombosis. The German Pharma will provide up to €139M to Isis, including an up-front payment of €89.6M. Under the terms of the agreement, Isis is eligible to receive up to €139M in near-term payments, including an immediate €89.6M up-front payment and […]

May 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 May 2015

Natural Killer therapies for Cancer: a Fast-Evolving field

Natural killers are an emerging approach to fight inflammatory diseases and cancer. These immune actors, that specifically regulate the activity of the immune system, are attracting the attention of several small startups and more than a few big Pharmas. The immune system includes a set of body defenses, that fight foreign forms. But external bodies aren’t […]

May 5, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Karolinska Development took a Step Back in its Biotech portfolio

The finances of Karolinska Development remain in a dangerous downward spiral as the company dropped to €136.9M (SEK 1,277 million), an unsatisfactory record for the company, the lowest valuation since 2011. For this purpose, the company decided to totally abandon investing in Pergamum, Umecrine and NeoDynamics AB, three biotech companies. Karolinska’s reaction is well-defined: the […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Sygnis on the way to conquer the UK Life Sciences market

Sygnis signed a distribution agreement with Cambridge Bioscience for the commercialization of its proprietary product portfolio in the UK and Ireland. This is a significant expansion of product roll-out into one of the most important life science markets in Europe. Under the terms and conditions of the agreement, Cambridge Bioscience will promote, market, sell and […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 May 2015

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with an incredible jump of +100% on its third day as a public company. Imeglimin, its lead candidate, is a Type 2 diabetes treatment (licensed by Merck Serono) on the launch of Phase III. This innovative compound is […]

May 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 2 May 2015

Newron raised new funds to continue the development of Neurological therapies

Newron Pharmaceuticals, a public company focused on novel Central Nervous System (CNS) and pain therapies, announces that it has completed a capital increase of approximately €23.2M (CHF24.3 million). This fundraising will be used to accelerate the development of Newron’s pipeline of innovative CNS therapeutics: The company priority seems to be on NW-3509, an add-on therapy for schizophrenia, for […]

May 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 2 May 2015

PlugMed has Just Won €2M Funding to Develop an Innovative Device against Kidney Failure

PlugMed has been awarded €2 million of funding, as part of the World Innovation Challenge organized by the French Ministry of Industry. It will enable the company to speed up the Geroneph project that aims at developing an innovative device in the treatment of kidney failure. Nowadays, dialysis is used by more than two million people […]

May 2, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 1 May 2015

Galderma steps into the Nutraceutical Market

Galderma entered the functional food market thanks to its acquisition of certain assets of Innéov Group. The company, a global leader committed to dermatology and skin health, is fully-owned by Nestlé Skin Health. On April 24th Nestlé Skin Health announced that Galderma, its company focused on medical solutions, has come to an agreement under which it […]

May 1, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 1 May 2015

Addex Therapeutics: When one of the leading Swiss Biotech startups relives

Biotech startups are risky. They need lot of cash to come across the very regulated clinical path and can fail rapidly when bad results show up. Addex Therapeutics, a Swiss Geneva-based Biotech company, has raised more than €200M throughout its existence and signed deals worth more than €1Bn with Merck and J&J. Yet, on the 31st May 2013, the company almost […]

May 1, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 30 Apr 2015

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B financing round with €79.5M. The oversubscribed financing rounds were led by strategic investors, GlaxoSmithKline‘s SR One and Celgene Corporation, respectively and also included other actors already known by the company, such as Versant Ventures, along with new ones namely New […]

April 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Apr 2015

A new Microfluidic Chip technology raised €1.9Million

Lunaphore Technologies closed a Series A financing round of €1.9M (CHF 2 millions). The round was led by Redalpine Venture Partners in Zurich with the participation of private investors from Switzerland and the United Kingdom. Lunaphore’s young team wants to use this cash to develop its first tissue diagnostics platform. The young Swiss medtech company, […]

April 30, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 29 Apr 2015

Biocartis shakes Euronext with an IPO that raised €100M

Last Monday, Belgian Biocartis launched an IPO that quickly raised €100M; the offering was closed a week ahead of schedule. The unquestionable interest of the investors, both in Belgium and internationally, shows the company’s potential and the appeal of its technology. The company, which raised €64.5M in September in a private financial round, intends to […]

April 29, 2015 - 1 minutemin - By Lourdes Riquelme

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us